Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.64 |
| ▸ | ANPEP | P15144 | 1/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.54 |
| ▸ | MAOA | P21397 | 1/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.54 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.54 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | SCN4A | P35499 | 2/20 | 0.46 |
| ▸ | ALPI | P09923 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | XIAP | P98170 | 1/20 | 0.44 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.44 |
| ▸ | TACR1 | P25103 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15250377 | 1.00 | EPHX1 (0.64) | EPHX1ANPEPSLC6A2TAAR1MAOA | |
| SCHEMBL20992605 | 1.00 | EPHX1 (0.64) | EPHX1ANPEPSLC6A2TAAR1MAOA | |
| SCHEMBL24312629 | 0.84 | EPHX1 (0.59) | EPHX1ANPEPSLC6A2TAAR1MAOA | |
| SCHEMBL20821476 | 0.84 | EPHX1 (0.59) | EPHX1ANPEPSLC6A2TAAR1MAOA | |
| SCHEMBL23986747 | 0.82 | SLC6A4 (0.42) | EPHX1ANPEPSLC6A2TAAR1SLC6A4 | |
| SCHEMBL23986762 | 0.82 | SLC6A4 (0.43) | EPHX1ANPEPSLC6A2TAAR1SLC6A4 | |
| SCHEMBL20763845 | 0.80 | TAAR1 (0.57) | SLC6A2TAAR1SLC6A4SLC7A5 | |
| SCHEMBL20763851 | 0.80 | TAAR1 (0.57) | SLC6A2TAAR1SLC6A4SLC7A5 | |
| SCHEMBL20763836 | 0.80 | EPHX1 (0.59) | EPHX1ANPEPSLC6A2TAAR1MAOA | |
| SCHEMBL2627109 | 0.80 | TRPA1 (0.43) | EPHX1TAAR1MAOASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814406-B2 | Compounds and methods for treatment of viral infections | GILEAD SCIENCES, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814406-B2 | Compounds and methods for treatment of viral infections | GILEAD SCIENCES, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230151043-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230151043-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20220081462-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2022-03-17 | — | — | US | disclosed |
| US-20100210552-A1 | HUMAN GLUCAGON-LIKE PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-19 | — | — | US | disclosed |
| US-20100210552-A1 | HUMAN GLUCAGON-LIKE PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-19 | — | — | US | disclosed |
| US-20070287670-A1 | HUMAN GLUCAGON-LIKE PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY | 2007-12-13 | — | — | US | disclosed |
| US-7238670-B2 | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287670-A1 | HUMAN GLUCAGON-LIKE PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | GLP1R, IAPP, GIPR | EPHX1 4048/4885ANPEP 99/4885SLC6A2 4493/4885 |
| US-20220081462-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, ACE | EPHX1 1802/4885ANPEP 666/4885SLC6A2 3311/4885 |
| US-11814406-B2 | Compounds and methods for treatment of viral infections | HAVCR2, EIF2AK2, ACE | EPHX1 1802/4885ANPEP 666/4885SLC6A2 3311/4885 |
| US-20100210552-A1 | HUMAN GLUCAGON-LIKE PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | GLP1R, IAPP, GIPR | EPHX1 4048/4885ANPEP 99/4885SLC6A2 4493/4885 |
| US-20230151043-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, ACE | EPHX1 1802/4885ANPEP 666/4885SLC6A2 3311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.